Flor Rivera
Family · Hickory, NCNPI 1336802115
Payments from drug & device makers
Across 121 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$401
- Mylan Specialty L.p.$369
- GSK$365
- Baxter Healthcare$180
- Takeda Pharmaceuticals U.S.A., Inc.$178
- Amgen$167
- plus $928 from 14 others
What the payments were for
- Food & beverage$2,49296%
- Education$954%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $401 |
| Mylan Specialty L.p. | 21 | $369 |
| GSK | 17 | $365 |
| Baxter Healthcare | 9 | $180 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $178 |
| Amgen | 8 | $167 |
| Boehringer Ingelheim | 7 | $165 |
| Inspire Medical Systems, Inc. | 4 | $144 |
| United Therapeutics Corporation | 6 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Actelion Pharmaceuticals US, Inc. | 3 | $82 |
| Regeneron Healthcare Solutions, Inc. | 3 | $77 |
| Insmed, Inc. | 3 | $59 |
| Pulmonx Corporation | 3 | $45 |
| ANI Pharmaceuticals, Inc. | 2 | $33 |
| Merck | 2 | $32 |
| Fisher & Paykel Healthcare Inc | 1 | $22 |
| Sanofi | 1 | $20 |
| Phadia US Inc. | 1 | $16 |
| Electromed, Inc. | 1 | $13 |
How this compares
$2,587 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 304 | $215,051 |
| GlassiaAlpha-1-Proteinase Inhibitor | 12 | $175,251 |
| TezspireTezepelumab-Ekko | 36 | $149,452 |
| Fasenra PenBenralizumab | 20 | $126,318 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 129 | $92,674 |
| NucalaMepolizumab | 14 | $59,242 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $33,657 |
| Spiriva RespimatTiotropium Bromide | 51 | $33,134 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $22,165 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 39 | $21,843 |
| Roflumilast | 116 | $19,073 |
| Incruse ElliptaUmeclidinium Bromide | 44 | $18,467 |
| Spiriva HandihalerTiotropium Bromide | 24 | $18,010 |
| SymbicortBudesonide/Formoterol Fumarate | 65 | $17,304 |
| Advair HfaFluticasone Propion/Salmeterol | 35 | $15,909 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $365 | $348,582476 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $401 | $259,431230 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $178 | $175,25112 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $165 | $65,018111 claims |
| MerckDulera | $32 | $5,20615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,522 family providers in North Carolina.
Other family in Hickory
- Kelly HolmesHickory$55K
- Tanya DyerHickory$21K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.